LA
REGN icon

Latitude Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Latitude Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-312
Closed -$218K – 287
2022
Q1 		$218K Buy
+312
New +$197K 0.05% 304

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Latitude Advisors's REGN Position: Q2 2022 in Review

Latitude Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 312 shares — an estimated $218K sold.

Latitude Advisors first reported a position in REGN in Q1 2022 and held it in 1 quarter. The position peaked at $218K in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Latitude Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Latitude Advisors sold 312 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $218K.
  • Latitude Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Latitude Advisors's Regeneron Pharmaceuticals position peaked at $218K in Q1 2022.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Latitude Advisors's 13F filing for Q2 2022, filed 28 Jul 2022.